Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aidi injection is a modernized Chinese herbal injection developed by Guizhou Yibai Pharmaceutical. It is a complex formulation containing extracts from four traditional Chinese medicines: *Panax ginseng* (Ginseng Radix et Rhizoma), *Astragalus mongholicus* (Astragali Radix), *Eleutherococcus senticosus* (Acanthopanacis Senticosi Radix Et Rhizoma Seu Caulis), and *Mylabris phalerata* (Cantharis). The preparation is primarily used in China as an adjuvant therapy for various malignancies, including hepatocellular carcinoma, non-small cell lung cancer, and colorectal cancer. Its mechanism of action involves inhibiting tumor cell proliferation, inducing apoptosis, and modulating the immune system. Key active components identified include cantharidin, ginsenosides (Rb1, Rg1), and astragalosides (IV). It is often used in combination with chemotherapy (e.g., doxorubicin, paclitaxel) to enhance clinical efficacy and reduce treatment-related toxicities such as leukopenia and gastrointestinal reactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aidi injection.